A Phase 2 Study to Evaluate the Triplet Combination of Pemetrexed Plus AB928 (Etrumadenant) + AB122 (Zimberelimab) in Patients With Previously Treated Advanced or Metastatic MTAP Deficient Urothelial Carcinoma
Phase 2
Recruiting
- Conditions
- Urothelial CarcinomaMetastatic Cancer
- Interventions
- First Posted Date
- 2022-04-20
- Last Posted Date
- 2024-06-25
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 20
- Registration Number
- NCT05335941
- Locations
- 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States
Phase II Study of Salvage Radiation Treatment After B-cell Maturation Antigen Chimeric Antigen Receptor T-cell Therapy for Relapsed Refractory Multiple Myeloma
Phase 2
Recruiting
- Conditions
- Malignant Plasma Cell NeoplasmMultiple MyelomaPlasma Cell Neoplasm
- Interventions
- Drug: Radiation Therapy
- First Posted Date
- 2022-04-20
- Last Posted Date
- 2024-10-08
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 30
- Registration Number
- NCT05336383
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
A Phase II Clinical Trial to Evaluate Safety and Efficacy of XmAb20717 in Advanced Rare Cancers
Phase 2
Suspended
- Conditions
- Peritoneal MesotheliomaHodgkin's LymphomaPleural MesotheliomaSmall Cell Lung CancerNeuroendocrine CarcinomasCervical CarcinomaMicrosatellite High CancersExtrapulmonary High Grade
- Interventions
- Drug: XmAb20717
- First Posted Date
- 2022-04-20
- Last Posted Date
- 2024-06-04
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 140
- Registration Number
- NCT05337735
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
First-in-Human Assessment of Safety, Biodistribution and Pharmacokinetics of 18F-Fluoro-1-Naphthol (18F-4FN) for PET Imaging
Phase 1
Active, not recruiting
- Conditions
- Endocrine Neoplasia
- Interventions
- Drug: 4-[18F]Fluoro-1-Naphthol
- First Posted Date
- 2022-04-19
- Last Posted Date
- 2024-08-26
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 30
- Registration Number
- NCT05335811
- Locations
- 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States
Attitudes and Believes About Vaccinations in a Supportive Care Patient Population
Completed
- Conditions
- Vaccinations
- Interventions
- Other: patient population
- First Posted Date
- 2022-04-15
- Last Posted Date
- 2024-07-17
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 104
- Registration Number
- NCT05329506
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Non-randomized, Open-label Study of Intralesional Nivolumab for High Risk Oral Premalignant Lesions
- First Posted Date
- 2022-04-14
- Last Posted Date
- 2024-08-02
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 18
- Registration Number
- NCT05327270
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Intraoperative Aromatherapy Versus Placebo for Port-a-Cath Placement Under Monitored Anesthesia Care. A Randomized Controlled Trial
Phase 2
Completed
- Conditions
- Cancer Pain
- Interventions
- Other: ELEQUIL
- First Posted Date
- 2022-04-14
- Last Posted Date
- 2024-12-02
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 70
- Registration Number
- NCT05328973
- Locations
- 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States
A Pilot Study of Glutamine PET Imaging of Head and Neck Squamous Cell Carcinoma
Early Phase 1
Active, not recruiting
- Conditions
- Head and Neck Squamous Cell CarcinomaHead and Neck Cancer
- Interventions
- Drug: 18F-FSPGDrug: 11C-Glutamine
- First Posted Date
- 2022-04-11
- Last Posted Date
- 2024-10-30
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 3
- Registration Number
- NCT05322135
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Pirtobrutinib (LOXO-305) Consolidation for MRD Eradication in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL) Treated With Venetoclax
Phase 2
Active, not recruiting
- Conditions
- Chronic Lymphocytic LeukemiaSmall Lymphocytic Lymphoma
- Interventions
- First Posted Date
- 2022-04-08
- Last Posted Date
- 2024-10-14
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 44
- Registration Number
- NCT05317936
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
POWER UP: Participating Online While Exercising to Recover Using Play
Not Applicable
Suspended
- Conditions
- ExerciseCentral Nervous System TumorsTumors
- Interventions
- Other: Focus GroupsOther: Pilot randomized controlled trial
- First Posted Date
- 2022-04-04
- Last Posted Date
- 2024-10-26
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 16
- Registration Number
- NCT05308407
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
© Copyright 2025. All Rights Reserved by MedPath